BioPharma Dive January 21, 2025
The biotech has been working with the support of BARDA to develop candidates that could protect against avian influenza viruses like the H5 and H7 strains.
Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as H5N1, that are seen as potential pandemic risks.
Announced Friday as one of the Biden administration’s final acts, the funding commitment is through the Biomedical Advanced Research and Development Authority, or BARDA, an arm of the Department of Health and Human Services.
BARDA and Moderna have worked together for years, including previously on the biotechnology company’s vaccine for COVID-19. The new grant expands on one issued to Moderna last summer.
Moderna has been testing...
Today's Sponsors
Today's Sponsor